Reviva Pharmaceuticals (NASDAQ:RVPH) Raised to Sell at Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts have also recently weighed in on the company. Benchmark reduced their price target on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating for the company in a report on Monday, September 15th. D. Boral Capital reduced their price target on Reviva Pharmaceuticals from $3.00 to $2.00 and set a “buy” rating for the company in a report on Friday, September 19th. Roth Capital reaffirmed a “buy” rating and issued a $3.00 price target (down previously from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Citigroup reaffirmed a “buy” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Saturday, September 27th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.86.

Reviva Pharmaceuticals Stock Up 11.7%

Shares of RVPH stock opened at $0.55 on Friday. The stock has a market cap of $37.79 million, a PE ratio of -0.84 and a beta of -0.08. Reviva Pharmaceuticals has a 52-week low of $0.25 and a 52-week high of $4.28. The business has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.62.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Sell-side analysts anticipate that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Institutional Trading of Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Ameriprise Financial Inc. acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth about $84,000. BluePointe Capital Management LLC increased its stake in Reviva Pharmaceuticals by 354.7% in the first quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock valued at $45,000 after purchasing an additional 36,807 shares during the last quarter. Private Advisor Group LLC acquired a new stake in Reviva Pharmaceuticals during the first quarter worth approximately $191,000. Armistice Capital LLC purchased a new stake in shares of Reviva Pharmaceuticals during the 2nd quarter worth approximately $1,026,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.